Evidence map›Paper›PMID 33716632›Full record

ArticleBreast care (Basel, Switzerland)2021

Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.

Rachel Wuerstlein, Nadia Harbeck, Eva-Maria Grischke, Dirk Forstmeyer, Raquel von Schumann, Petra Krabisch, Kerstin Lüdtke-Heckenkamp, Andrea Stefek, Oliver Stoetzer, Andrea Grafe and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rachel WuerstleinBreast Center and CCC Munich, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany.
Nadia HarbeckBreast Center and CCC Munich, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany.
Eva-Maria GrischkeUniversity Clinic Tübingen, Women's Clinic, Tübingen, Germany.
Dirk ForstmeyerUniversity Clinic Leipzig, University Cancer Center Leipzig (UCCL), Leipzig, Germany.
Raquel von SchumannEvangelical Hospital Bethesda, Breast Center Niederrhein, Mönchengladbach, Germany.
Petra KrabischClinic Chemnitz, Breast Center, Chemnitz, Germany.
Kerstin Lüdtke-HeckenkampNiels Stensen Clinics, Franziskus Hospital Harderberg, Georgsmarienhütte, Germany.
Andrea StefekJohanniter Clinics Stendal, Breast Center Altmark, Stendal, Germany.
Oliver StoetzerMedical Center for Hematology and Oncology Munich, Munich, Germany.
Andrea GrafeMVZ Nordhausen, Nordhausen, Germany.
Gabriele KalteneckerMunicipal Clinic Karlsruhe, Breast Center, Karlsruhe, Germany.
Helmut ForstbauerPractice Network Troisdorf, Troisdorf, Germany.
Doris AugustinDonau-Isar Clinic Deggendorf, Breast Center, Deggendorf, Germany.
Iris SchraderGynecological Oncological Practice Hanover, Hanover, Germany.
Joke TioUniversity Clinic Münster, Breast Center, Münster, Germany.
Ulrike NitzWest German Study Group, Mönchengladbach, Germany.
Oleg GluzWest German Study Group, Mönchengladbach, Germany.
Ronald E KatesWest German Study Group, Mönchengladbach, Germany.
Monika Karla GraeserWest German Study Group, Mönchengladbach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProtroca evaluated the efficacy and safety of primary and secondary prophylaxis of neutropenia with lipegfilgrastim (Lonquex®) in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy (CT). PATIENTS AND

methodsOf the 255 patients enrolled, 248 patients were evaluable for the intent-to-treat (ITT) and 194 patients for the per-protocol set. Primary and secondary end points after lipegfilgrastim treatment were assessed.

resultsNine patients of the ITT set receiving lipegfilgrastim as primary prophylaxis (

conclusionsApplication of lipegfilgrastim was effective as primary and secondary prophylaxis in the prevention of CT-induced neutropenia in breast cancer.

Indexed as

Breast cancerChemotherapyFebrile neutropenia prophylaxisLipegfilgrastim

Identifiers

PMID33716632
PMCPMC7923841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.